Heart rate: A global target for cardiovascular disease and therapy along the cardiovascular disease continuum

Journal of Cardiology

Volumn 62, Issue 3, 2013, Pages 183-187

  Custodis, Florian ^a   Reil, Jan Christian ^a   Laufs, Ulrich ^a   Böhm, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Cardiovascular disease continuum; Heart rate; I(f) current inhibition; Risk reduction

Indexed keywords

IVABRADINE;

ARTICLE; ATHEROSCLEROSIS; BETA ADRENERGIC RECEPTOR BLOCKING; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; ISCHEMIC HEART DISEASE; NEUROLOGICAL COMPLICATION; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIMARY PREVENTION; RESTING HEART RATE; SECONDARY PREVENTION; STABLE ANGINA PECTORIS;

CARDIOVASCULAR DISEASE CONTINUUM; HEART RATE; I(F) CURRENT INHIBITION; RISK REDUCTION;

ATHEROSCLEROSIS; BENZAZEPINES; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HEART RATE; HUMANS; PROGNOSIS; REST; RISK; RISK FACTORS; STROKE;

EID: 84883559372     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.02.018     Document Type: Article

References (56)

1. Custodis F., Schirmer S.H., Baumhäkel M., Heusch G., Böhm M., Laufs U. Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol 2010, 56:1973-1983.
2. Kannel W.B., Kannel C., Paffenbarger R.S., Cupples L.A. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987, 113:1489-1494.
3. Gillman M.W., Kannel W.B., Belanger A., D'Agostino R.B. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993, 125:1148-1154.
4. Diaz A., Bourassa M.G., Guertin M.C., Tardif J.C. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005, 26:967-974.
5. Böhm M., Swedberg K., Komajda M., Borer J.S., Ford I., Dubost-Brama A., Lerebours G., Tavazzi L. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010, 376:886-894.
6. Hjalmarson A., Gilpin E.A., Kjekshus J., Schieman G., Nicod P., Henning H., Ross J. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990, 65:547-553.
7. Reil J.C., Custodis F., Swedberg K., Komajda M., Borer J.S., Ford I., Tavazzi L., Laufs U., Böhm M. Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 2011, 100:11-19.
8. Dzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991, 121:1244-1263.
9. Fox K., Borer J.S., Camm A.J., Danchin N., Ferrari R., Lopez Sendon J.L., Steg P.G., Tardif J.C., Tavazzi L., Tendera M. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007, 50:823-830.
10. Shigetoh Y., Adachi H., Yamagishi S., Enomoto M., Fukami A., Otsuka M., Kumagae S., Furuki K., Nanjo Y., Imaizumi T. Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general population. Am J Hypertens 2009, 22:151-155.
11. Carnethon M.R., Yan L., Greenland P., Garside D.B., Dyer A.R., Metzger B., Daviglus M.L. Resting heart rate in middle age and diabetes development in older age. Diabetes Care 2008, 31:335-339.
12. Levy R.L., White P.D., Stroud W.D. Transient tachycardia: prognostic significance alone and in association with transient hypertension. JAMA 1945, 129:585-588.
13. Palatini P., Graniero G.R., Mormino P., Nicolosi L., Mos L., Visentin P., Pessina A.C. Relation between physical training and ambulatory blood pressure in stage I hypertensive subjects. Results of the HARVEST Trial. Hypertension and Ambulatory Recording Venetia Study. Circulation 1994, 90:2870-2876.
14. Schmieder R.E., Schrader J., Zidek W., Tebbe U., Paar W.D., Bramlage P., Pittrow D., Böhm M. Low-grade albuminuria and cardiovascular risk: what is the evidence?. Clin Res Cardiol 2007, 96:247-257.
15. Böhm M., Reil J.C., Danchin N., Thoenes M., Bramlage P., Volpe M. Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH. J Hypertens 2008, 26:18-25.
16. Böhm M., Thoenes M., Neuberger H.R., Graber S., Reil J.C., Bramlage P., Volpe M. Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients. Eur Heart J 2009, 30:1364-1371.
17. Beere P.A., Glagov S., Zarins C.K. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984, 226:180-182.
18. Custodis F., Baumhäkel M., Schlimmer N., List F., Gensch C., Böhm M., Laufs U. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008, 117:2377-2387.
19. Drouin A., Gendron M.E., Thorin E., Gillis M.A., Mahlberg-Gaudin F., Tardif J.C. Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br J Pharmacol 2008, 154:749-757.
20. Baumhäkel M., Custodis F., Schlimmer N., Laufs U., Böhm M. Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice. Atherosclerosis 2010, 212:55-62.
21. Schirmer S.H., Degen A., Baumhäkel M., Custodis F., Schuh L., Kohlhaas M., Friedrich E., Bahlmann F., Kappl R., Maack C., Böhm M., Laufs U. Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. Eur Heart J 2012, 33:1223-1231.
22. Custodis F., Fries P., Müller A., Stamm C., Grube M., Kroemer H.K., Böhm M., Laufs U. Heart rate reduction by ivabradine improves aortic compliance in apolipoprotein E-deficient mice. J Vasc Res 2012, 49:432-440.
23. Reil J.C., Hohl M., Reil G.H., Granzier H.L., Kratz M.T., Kazakov A., Fries P., Müller A., Lenski M., Custodis F., Graber S., Fröhlig G., Steendijk P., Neuberger H.R., Böhm M. Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J 2012, (July). [Epub ahead of print].
24. Bolduc V., Drouin A., Gillis M.A., Duquette N., Thorin-Trescases N., Frayne-Robillard I., Des Rosiers C., Tardif J.C., Thorin E. Heart rate-associated mechanical stress impairs carotid but not cerebral artery compliance in dyslipidemic atherosclerotic mice. Am J Physiol Heart Circ Physiol 2011, 301:H2081-H2092.
25. O'Hartaigh B., Bosch J.A., Carroll D., Hemming K., Pilz S., Loerbroks A., Kleber M.E., Grammer T.B., Fischer J.E., Boehm B.O., Marz W., Thomas G.N. Evidence of a synergistic association between heart rate, inflammation, and cardiovascular mortality in patients undergoing coronary angiography. Eur Heart J 2012, (November). [Epub ahead of print].
26. Nanchen D., Stott D.J., Gussekloo J., Mooijaart S.P., Westendorp R.G., Jukema J.W., Macfarlane P.W., Cornuz J., Rodondi N., Buckley B.M., Ford I., Sattar N., de Craen A.J. Resting heart rate and incident heart failure and cardiovascular mortality in older adults: role of inflammation and endothelial dysfunction: the PROSPER study. Eur J Heart Fail 2012, (December). [Epub ahead of print].
27. Benjamin E.J., Larson M.G., Keyes M.J., Mitchell G.F., Vasan R.S., Keaney J.F., Lehman B.T., Fan S., Osypiuk E., Vita J.A. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation 2004, 109:613-619.
28. Nerla R., Di Franco A., Milo M., Pitocco D., Zaccardi F., Tarzia P., Sarullo F.M., Villano A., Russo G., Stazi A., Ghirlanda G., Lanza G.A., Crea F. Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients. Heart 2012, 98:1812-1816.
29. Chatzizisis Y.S., Coskun A.U., Jonas M., Edelman E.R., Feldman C.L., Stone P.H. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol 2007, 49:2379-2393.
30. Bassiouny H.S., Zarins C.K., Kadowaki M.H., Glagov S. Hemodynamic stress and experimental aortoiliac atherosclerosis. J Vasc Surg 1994, 19:426-434.
31. Giannoglou G.D., Chatzizisis Y.S., Zamboulis C., Parcharidis G.E., Mikhailidis D.P., Louridas G.E. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol 2008, 126:302-312.
32. Fox K., Ford I., Steg P.G., Tendera M., Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:807-816.
33. Fox K., Ford I., Steg P.G., Tendera M., Robertson M., Ferrari R. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009, 30:2337-2345.
34. Heidland U.E., Strauer B.E. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001, 104:1477-1482.
35. Zuanetti G., Hernandes-Bernal F., Rossi A., Comerio G., Paolucci G., Maggioni A.P. Relevance of heart rate as a prognostic factor in myocardial infarction: the GISSI experience. Eur Heart J 1999, 1(Suppl. H):H52-H57.
36. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol 2008, 153:1589-1601.
37. Fox K., Garcia M.A., Ardissino D., Buszman P., Camici P.G., Crea F., Daly C., De Backer G., Hjemdahl P., Lopez-Sendon J., Marco J., Morais J., Pepper J., Sechtem U., Simoons M., et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006, 27:1341-1381.
38. Steg P.G., James S.K., Atar D., Badano L.P., Blomstrom-Lundqvist C., Borger M.A., Di Mario C., Dickstein K., Ducrocq G., Fernandez-Aviles F., Gershlick A.H., Giannuzzi P., Halvorsen S., Huber K., Juni P., et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012, 33:2569-2619.
39. Bangalore S., Steg G., Deedwania P., Crowley K., Eagle K.A., Goto S., Ohman E.M., Cannon C.P., Smith S.C., Zeymer U., Hoffman E.B., Messerli F.H., Bhatt D.L. Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012, 308:1340-1349.
40. Steg P.G., Ferrari R., Ford I., Greenlaw N., Tardif J.C., Tendera M., Abergel H., Fox K.M. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS ONE 2012, 7:e36284.
41. Berdeaux A. Preclinical results with I(f) current inhibition by ivabradine. Drugs 2007, 67(Suppl. 2):25-33.
42. Tardif J.C., Ponikowski P., Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009, 30:540-548.
43. Borer J.S., Fox K., Jaillon P., Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003, 107:817-823.
44. Tardif J.C., Ford I., Tendera M., Bourassa M.G., Fox K. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005, 26:2529-2536.
45. Kaye D.M., Lefkovits J., Jennings G.L., Bergin P., Broughton A., Esler M.D. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995, 26:1257-1263.
46. Böhm M. Pathophysiology of heart failure today. Herz 2002, 27:75-91.
47. Umana E., Solares C.A., Alpert M.A. Tachycardia-induced cardiomyopathy. Am J Med 2003, 114:51-55.
48. McAlister F.A., Wiebe N., Ezekowitz J.A., Leung A.A., Armstrong P.W. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009, 150:784-794.
49. Lechat P., Escolano S., Golmard J.L., Lardoux H., Witchitz S., Henneman J.A., Maisch B., Hetzel M., Jaillon P., Boissel J.P., Mallet A. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation 1997, 96:2197-2205.
50. Lechat P., Hulot J.S., Escolano S., Mallet A., Leizorovicz A., Werhlen-Grandjean M., Pochmalicki G., Dargie H. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001, 103:1428-1433.
51. Flannery G., Gehrig-Mills R., Billah B., Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008, 101:865-869.
52. Swedberg K., Komajda M., Böhm M., Borer J.S., Ford I., Dubost-Brama A., Lerebours G., Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010, 376:875-885.
53. Laufs U., Gertz K., Dirnagl U., Böhm M., Nickenig G., Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002, 942:23-30.
54. Prinz V., Laufs U., Gertz K., Kronenberg G., Balkaya M., Leithner C., Lindauer U., Endres M. Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke 2008, 39:433-438.
55. Custodis F., Gertz K., Balkaya M., Prinz V., Mathar I., Stamm C., Kronenberg G., Kazakov A., Freichel M., Böhm M., Endres M., Laufs U. Heart rate contributes to the vascular effects of chronic mental stress: effects on endothelial function and ischemic brain injury in mice. Stroke 2011, 42:1742-1749.
56. Böhm M., Cotton D., Foster L., Custodis F., Laufs U., Sacco R., Bath P.M., Yusuf S., Diener H.C. Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke. Eur Heart J 2012, 33:2804-2812.